Sandra Johnson, MD
Glaucoma Specialist · Columbia, MONPI 1730198714
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,626 of the $17,442 with a category attached, or 60.9%. 21 manufacturers reported payments, led by AbbVie at 56.6% of the total. Reporting peaked in 2019 at $9,023 and has fallen 83.7% since, to $1,473 in 2025.
Across 199 payments — averaging $87.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- NEW World Medical,inc.$1K
- Sight Sciences, Inc.$1K
- Alcon$1K
- Glaukos Corporation$643
- Sun Pharmaceutical Industries Inc.$538
- plus $3K from 15 others
What the payments were for
- Consulting fees$6,00034%
- Travel & lodging$6164%
- Food & beverage$10,62661%
- Education$2001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $9,866 |
| NEW World Medical,inc. | 14 | $1,279 |
| Sight Sciences, Inc. | 17 | $1,276 |
| Alcon | 25 | $1,237 |
| Glaukos Corporation | 5 | $643 |
| Sun Pharmaceutical Industries Inc. | 11 | $538 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $479 |
| Aerie Pharmaceuticals, Inc. | 9 | $431 |
| Ivantis, Inc | 6 | $349 |
| Carl Zeiss Meditec USA, Inc. | 7 | $315 |
| Bausch & Lomb Americas Inc. | 4 | $248 |
| Thea Pharma Inc. | 2 | $200 |
| Eyevance Pharmaceuticals LLC | 1 | $149 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Dompe US, Inc. | 1 | $121 |
| Novartis | 4 | $73 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $52 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN$6,849
- XEN GLAUCOMA TREATMENT SYSTEM$826
- Ahmed Glaucoma Valve$721
- Kahook Dual Blade$721
- OMNI(R) SURGICAL SYSTEM (US)$584
- Rocklatan$498
- DURYSTA$256
- LUMIGAN$226
- Hydrus Microstent$210
- iStent infinite Trabecular Micro-Bypass System Model iS3$151
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$151
- Clearpath$150
- Streamline$150
- Flarex$149
- iDose$146
- iDoseTR$142
- Hydrus$132
- Centurion$127
- QUATERA 700$126
- CEQUA$125
How this compares
Too few glaucoma specialist providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 108 | $48,697 |
| RhopressaNetarsudil Mesylate | 88 | $37,781 |
| RocklatanNetarsudil Mesylat/Latanoprost | 68 | $30,336 |
| CombiganBrimonidine Tartrate/Timolol | 63 | $20,708 |
| RestasisCyclosporine | 16 | $12,626 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 71 | $10,572 |
| Alphagan PBrimonidine Tartrate | 25 | $9,287 |
| VyzultaLatanoprostene Bunod | 14 | $7,839 |
| Latanoprost | 671 | $7,197 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 46 | $6,908 |
| Brimonidine Tartrate | 205 | $5,805 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 296 | $5,747 |
| Prednisolone Acetate | 75 | $2,445 |
| Timolol Maleate | 222 | $1,987 |
| Fluorometholone | 22 | $1,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $9,866 | $91,318212 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $431 | $68,117156 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $248 | $7,83914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Missourion file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Columbia
- Abhinav GollaColumbia$3K
- Aaron WebelColumbia$3K
- Arsham SheybaniSaint Louis$860K
- Giovanni CampagnaSaint Louis$56K
- Ariana LevinSaint Louis$25K
- James LiuSaint Louis$21K
- Erin SieckSaint Louis$8K
- Carla SiegfriedSaint Louis$6K
- Benjamin KatzSaint Louis$4K
- Sharon SabapathypillaiSaint Louis$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.